<DOC>
	<DOCNO>NCT02133664</DOCNO>
	<brief_summary>The primary aim collect data determine correct effect size primary outcome aid design large study : The primary outcome determine lipoic acid omega-3 fatty acid improve cognitive function people multiple sclerosis cognitive dysfunction .</brief_summary>
	<brief_title>Lipoic Acid Omega-3 Fatty Acids Cognitive Impairment Multiple Sclerosis</brief_title>
	<detailed_description>The study design randomize , double-blind , placebo-controlled pilot trial . The primary aim study determine lipoic acid omega-3 fatty acid improve cognitive function 12-weeks people multiple sclerosis baseline score least two standard deviation normative value one four cognitive test include , Paced Auditory Serial Addition Task ( PASAT ) , Stroop Color-Word Test , California Verbal Learning Test-II ( CVLT-II ) , Controlled Oral Word Association Test ( COWAT ) . The secondary aim determine treatment effect marker endothelial inflammation , insulin dysregulation , mitochondrial dysfunction may relate cognitive dysfunction measure s-ICAM-1 level , homeostasis model insulin resistance ( HOMA-IR ) , MRI phosphorus image subset study participant . The study also measure safety adverse event report laboratory measure ; plasma fatty acid level ; serum lipoic acid level .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Thioctic Acid</mesh_term>
	<criteria>• A definite diagnosis MS relapse remit secondary progressive course Age 18 65 year , inclusive A score two standard deviation mean one follow cognitive test : PASAT , COWAT , CVLT II , Stroop Expanded Disability Status Scale ( EDSS ) 07.5 , inclusive Suboptimal omega3 level ( plasma DHA + EPA &lt; 5.0 % total plasma fatty acid ) If take MS disease modify medication , stable dose &gt; 6 month precede enrollment Able read write English • Moderate severe depression ( Beck Depression Inventory score &gt; 19 ) Any significant uncontrolled medical problem include diabetes require insulin . MS relapse within 30 day screen Abnormalities coagulation current use prescription anticoagulant antiplatelet agent . Aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) exclude . Fish intake one 6 ounce serve &gt; week le 2 month prior enrollment Omega3 fatty acid supplement intake ( e.g . fish oil capsule , cod liver oil ) less 2 month prior enrollment Lipoic Acid supplementation le 1 month prior enrollment Taking systemic corticosteroid , neuroleptic , antiparkinsonian agent , and/or narcotic analgesic . Low dose sinemet dopamine agonist take day restless leg syndrome exclusion . Contraindications MRI , include : subject intrathecal pump , stimulators , pacemaker , aneurysm clip , nonremovable hearing aid , metal fragment eye . Other exclusion criterion include inability lie flat back 40 minute time selfreported history claustrophobia . Subjects history hip replacement welldocumented , verifiable , MRIsafe cardiac stent exclude study . Epilepsy history seizure . Pregnancy woman use reliable form contraception Corrected binocular visual acuity bad 20/50 one error binocular color vision test Ishihara Color plate sustain nystagmus diplopia primary gaze Inability complete neuropsychological test battery screen visit Participation another intervention study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>cognition</keyword>
	<keyword>clinical trial</keyword>
	<keyword>thiotic acid</keyword>
	<keyword>Omega-3 fatty acid</keyword>
</DOC>